All for Joomla All for Webmasters

Opposition objects to Undue Bureaucracy killing the Cannabis Licensing Authority (CLA)

Opposition objects to Undue Bureaucracy killing the Cannabis Licensing Authority (CLA)

Following an online media report that “investors are being frustrated by the bureaucratic inertia within the CLA”, Opposition Spokesman on Industry, Investment and Commerce, Anthony Hylton, is today calling on the Government to articulate a clear vision and policy for the development of the legal Medical Ganja Industry in Jamaica.

The former Minister under whose direction the CLA was established, detailed industry blueprint and draft Interim Regulations were developed, is expressing deep concern over the content of the Report.

Mr. Hyltonsaid “the state of affairs at the CLA has been shrouded in mystery ever since the Administration took office in February of this year”. He further states that “after a sufficient period of review, the time has come for the Administration to speak with one coherent voice on its policies and plans for the Industry”.

The Opposition notes that the early decisions taken by the Administration to reverse key elements in the draft Interim Regulations left by the PNP Administration, such as the non-payment of licence fees for small farmers growing less than half-an-acre of Ganja in the first few years coupled with an apparent decision to subject licensing applications to comments from a myriad of ministries and agencies, could be the death knell of the CLA and with it the path-breaking developments in Jamaica’s ambition to be a leading light in the emergent Cannabis Industry and global market for medical marijuana products and related services.

The Spokesman confirmed the online report of “significant investor interests” in this potentially lucrative sector as being frustrated by the lack of action by the Administration in giving clear direction to Investors interested in the Industry.

Mr. Hylton is calling on the Government to act in a timely manner to preserve Jamaica’s brand in the emergent global Medical Cannabis Industry.